RTRX Biotech Retrophin

--- - Zacks Investment Research upgraded shares of Travere Therapeutics (NASDAQ:TVTX) from a sell rating to a hold rating in a research report report published on Wednesday, Zacks.com reports. According to Zacks, Travere Therapeutics Inc. is a biopharmaceutical company. It engages to identify, ...

--- - Shares of Travere Therapeutics, Inc. (NASDAQ:RTRX) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $27.76 and last traded at $26.88, with a volume of 302358 shares. The stock had previously closed at $27.05. A number of equities research analysts recently ...

--- - NEW YORK Thats another no for the Pharma Bro.A federal judge has rejected convicted pharmaceutical executives Martin Shkrelis second request to be let out of prison early, showing skepticism about his claim in court papers that mental health issues have weakened his immune system and made him more ...

--- - Zacks Investment Research cut shares of Travere Therapeutics (NASDAQ:TVTX) from a hold rating to a sell rating in a research note released on Friday, Zacks.com reports. According to Zacks, Travere Therapeutics Inc. is a biopharmaceutical company. It engages to identify, develop and deliver ...

--- - Cubist Systematic Strategies LLC lessened its position in shares of Travere Therapeutics, Inc. (NASDAQ:RTRX) by 36.2% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 31,516 shares of the biopharmaceutical companys stock after ...

--- - Travere Therapeutics, Inc. (NASDAQ:RTRX)s share price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $28.06 and last traded at $27.04, with a volume of 220708 shares traded. The stock had previously closed at $27.45. RTRX has been the subject of several recent...